NASDAQ:ENLV

Enlivex Therapeutics Competitors

$9.63
-1.00 (-9.41 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.36
Now: $9.63
$10.24
50-Day Range
$10.60
MA: $12.24
$14.89
52-Week Range
$4.49
Now: $9.63
$29.40
Volume209,085 shs
Average Volume404,612 shs
Market Capitalization$151.77 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14

Competitors

Enlivex Therapeutics (NASDAQ:ENLV) Vs. RIGL, ALBO, ANAB, IDYA, CLVS, and SIGA

Should you be buying ENLV stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Enlivex Therapeutics, including Rigel Pharmaceuticals (RIGL), Albireo Pharma (ALBO), AnaptysBio (ANAB), IDEAYA Biosciences (IDYA), Clovis Oncology (CLVS), and SIGA Technologies (SIGA).

Rigel Pharmaceuticals (NASDAQ:RIGL) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.

Earnings & Valuation

This table compares Rigel Pharmaceuticals and Enlivex Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rigel Pharmaceuticals$59.29 million10.19$-66,890,000.00($0.40)-8.88
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-8.68

Enlivex Therapeutics has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Rigel Pharmaceuticals and Enlivex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rigel Pharmaceuticals-26.25%-44.96%-20.08%
Enlivex TherapeuticsN/A-34.60%-28.47%

Insider & Institutional Ownership

82.0% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 4.7% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Rigel Pharmaceuticals has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Rigel Pharmaceuticals and Enlivex Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rigel Pharmaceuticals01302.75
Enlivex Therapeutics00103.00

Rigel Pharmaceuticals currently has a consensus target price of $8.3333, suggesting a potential upside of 134.74%. Enlivex Therapeutics has a consensus target price of $33.00, suggesting a potential upside of 242.68%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Rigel Pharmaceuticals.

Summary

Rigel Pharmaceuticals beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks.

Enlivex Therapeutics (NASDAQ:ENLV) and Albireo Pharma (NASDAQ:ALBO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Risk and Volatility

Enlivex Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Albireo Pharma has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

2.4% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 85.7% of Albireo Pharma shares are owned by institutional investors. 5.0% of Albireo Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Enlivex Therapeutics and Albireo Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enlivex TherapeuticsN/A-34.60%-28.47%
Albireo Pharma-751.53%-71.22%-42.91%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Enlivex Therapeutics and Albireo Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enlivex Therapeutics00103.00
Albireo Pharma00803.00

Enlivex Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 242.68%. Albireo Pharma has a consensus price target of $72.00, suggesting a potential upside of 128.50%. Given Enlivex Therapeutics' higher possible upside, research analysts plainly believe Enlivex Therapeutics is more favorable than Albireo Pharma.

Earnings & Valuation

This table compares Enlivex Therapeutics and Albireo Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-8.68
Albireo Pharma$9.64 million62.48$-62,720,000.00($5.04)-6.25

Enlivex Therapeutics has higher earnings, but lower revenue than Albireo Pharma. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks.

Enlivex Therapeutics (NASDAQ:ENLV) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Enlivex Therapeutics and AnaptysBio, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enlivex Therapeutics00103.00
AnaptysBio13302.29

Enlivex Therapeutics currently has a consensus price target of $33.00, indicating a potential upside of 242.68%. AnaptysBio has a consensus price target of $30.2857, indicating a potential upside of 38.23%. Given Enlivex Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than AnaptysBio.

Earnings & Valuation

This table compares Enlivex Therapeutics and AnaptysBio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-8.68
AnaptysBio$8 million74.95$-97,340,000.00($3.60)-6.09

Enlivex Therapeutics has higher earnings, but lower revenue than AnaptysBio. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enlivex Therapeutics and AnaptysBio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enlivex TherapeuticsN/A-34.60%-28.47%
AnaptysBioN/A-19.09%-17.94%

Volatility and Risk

Enlivex Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Insider & Institutional Ownership

2.4% of Enlivex Therapeutics shares are owned by institutional investors. 13.0% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IDEAYA Biosciences (NASDAQ:IDYA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations and earnings.

Profitability

This table compares IDEAYA Biosciences and Enlivex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
IDEAYA BiosciencesN/A-28.83%-22.92%
Enlivex TherapeuticsN/A-34.60%-28.47%

Volatility & Risk

IDEAYA Biosciences has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500.

Valuation & Earnings

This table compares IDEAYA Biosciences and Enlivex Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IDEAYA BiosciencesN/AN/A$-41,970,000.00($3.36)-5.52
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-8.68

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for IDEAYA Biosciences and Enlivex Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
IDEAYA Biosciences00603.00
Enlivex Therapeutics00103.00

IDEAYA Biosciences presently has a consensus price target of $31.4444, suggesting a potential upside of 69.42%. Enlivex Therapeutics has a consensus price target of $33.00, suggesting a potential upside of 242.68%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than IDEAYA Biosciences.

Insider & Institutional Ownership

62.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 20.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

IDEAYA Biosciences beats Enlivex Therapeutics on 7 of the 10 factors compared between the two stocks.

Enlivex Therapeutics (NASDAQ:ENLV) and Clovis Oncology (NASDAQ:CLVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Enlivex Therapeutics and Clovis Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enlivex Therapeutics00103.00
Clovis Oncology12102.00

Enlivex Therapeutics presently has a consensus target price of $33.00, suggesting a potential upside of 242.68%. Clovis Oncology has a consensus target price of $7.00, suggesting a potential upside of 23.46%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Clovis Oncology.

Valuation & Earnings

This table compares Enlivex Therapeutics and Clovis Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-8.68
Clovis Oncology$143.01 million4.14$-400,420,000.00($7.60)-0.75

Enlivex Therapeutics has higher earnings, but lower revenue than Clovis Oncology. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Clovis Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enlivex Therapeutics and Clovis Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enlivex TherapeuticsN/A-34.60%-28.47%
Clovis Oncology-230.34%N/A-57.56%

Institutional & Insider Ownership

2.4% of Enlivex Therapeutics shares are held by institutional investors. Comparatively, 57.8% of Clovis Oncology shares are held by institutional investors. 6.6% of Clovis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk & Volatility

Enlivex Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Clovis Oncology has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.

SIGA Technologies (NASDAQ:SIGA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and valuation.

Risk and Volatility

SIGA Technologies has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Profitability

This table compares SIGA Technologies and Enlivex Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SIGA Technologies34.62%37.31%25.33%
Enlivex TherapeuticsN/A-34.60%-28.47%

Institutional & Insider Ownership

29.3% of SIGA Technologies shares are held by institutional investors. Comparatively, 2.4% of Enlivex Therapeutics shares are held by institutional investors. 3.9% of SIGA Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for SIGA Technologies and Enlivex Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
SIGA Technologies0000N/A
Enlivex Therapeutics00103.00

Enlivex Therapeutics has a consensus target price of $33.00, indicating a potential upside of 242.68%. Given Enlivex Therapeutics' higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than SIGA Technologies.

Earnings and Valuation

This table compares SIGA Technologies and Enlivex Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SIGA Technologies$26.74 million21.74$-7,240,000.00N/AN/A
Enlivex TherapeuticsN/AN/A$-9,380,000.00($1.11)-8.68

SIGA Technologies has higher revenue and earnings than Enlivex Therapeutics.

Summary

SIGA Technologies beats Enlivex Therapeutics on 8 of the 11 factors compared between the two stocks.


Enlivex Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.55-2.0%$603.93 million$59.29 million-23.67Increase in Short Interest
News Coverage
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$31.51-4.4%$602.28 million$9.64 million-5.13
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.91-0.7%$599.59 million$8 million-8.08
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.56-1.0%$598.75 millionN/A-9.87Analyst Report
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.67-1.9%$592.69 million$143.01 million-1.08
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.58-5.3%$581.37 million$26.74 million18.94News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.67-0.5%$580.62 millionN/A-16.05
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$10.84-6.5%$578.15 millionN/A-4.35Analyst Upgrade
News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$23.61-2.1%$573.91 million$12.69 million-11.35Increase in Short Interest
News Coverage
Gap Up
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.0$42.87-0.6%$566.61 million$195.89 million122.49
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.55-2.3%$546.63 million$1.19 million-6.90
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$17.86-0.6%$543.69 millionN/A-5.19
OrganiGram logo
OGI
OrganiGram
1.6$2.34-11.1%$543.51 million$64.61 million-3.44Analyst Downgrade
Decrease in Short Interest
Gap Down
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.24-0.0%$531.75 millionN/A-3.15
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.84-1.0%$526.59 millionN/A-4.63News Coverage
Aldeyra Therapeutics logo
ALDX
Aldeyra Therapeutics
1.4$11.02-1.1%$523.94 millionN/A-8.54
89bio logo
ETNB
89bio
1.6$25.81-1.9%$517.10 millionN/A-5.11Insider Selling
CytomX Therapeutics logo
CTMX
CytomX Therapeutics
1.6$7.96-4.5%$515.68 million$57.49 million-6.69News Coverage
Magenta Therapeutics logo
MGTA
Magenta Therapeutics
1.3$10.61-1.0%$515.18 millionN/A-5.44
RAPT Therapeutics logo
RAPT
RAPT Therapeutics
1.6$20.64-3.0%$513.23 millionN/A-8.13
Inventiva logo
IVA
Inventiva
0.0$13.27-0.9%$512.62 millionN/A0.00
Neoleukin Therapeutics logo
NLTX
Neoleukin Therapeutics
1.4$12.04-0.2%$509.61 million$25 million-18.52
Marinus Pharmaceuticals logo
MRNS
Marinus Pharmaceuticals
1.7$13.85-1.2%$507.37 millionN/A-3.99
Akouos logo
AKUS
Akouos
1.6$14.60-2.4%$502.27 millionN/A0.00
Provention Bio logo
PRVB
Provention Bio
1.6$7.81-3.1%$494.96 millionN/A-5.24Analyst Report
Increase in Short Interest
XBiotech logo
XBIT
XBiotech
1.0$16.48-1.7%$485.48 millionN/A1.14News Coverage
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$13.50-1.9%$484.34 million$58.12 million-15.70Gap Up
Avadel Pharmaceuticals logo
AVDL
Avadel Pharmaceuticals
1.5$8.18-3.5%$478.24 million$59.22 million40.90
AC Immune logo
ACIU
AC Immune
1.3$6.51-0.0%$468.31 million$111.75 million-7.23Analyst Upgrade
Analyst Revision
Verastem logo
VSTM
Verastem
1.3$2.71-0.4%$465.22 million$17.46 million-1.92
Evolus logo
EOLS
Evolus
1.5$10.55-0.7%$461.38 million$34.92 million-5.20
TherapeuticsMD logo
TXMD
TherapeuticsMD
1.5$1.17-0.9%$460.03 million$49.65 million-1.65
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.39-1.8%$455.79 million$102.31 million6.55Increase in Short Interest
Forte Biosciences logo
FBRX
Forte Biosciences
1.7$33.20-7.7%$448.50 million$40,000.00-1.44Upcoming Earnings
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.81-1.7%$448.40 millionN/A-11.86
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.91-0.7%$447.35 million$109.33 million-2.14
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.96-4.1%$446.17 million$22.27 million-3.90Analyst Revision
Geron logo
GERN
Geron
1.4$1.40-0.0%$445.94 million$460,000.00-4.00Decrease in Short Interest
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.58-2.1%$439.15 millionN/A-2.30
Altimmune logo
ALT
Altimmune
1.9$11.81-0.3%$438.74 million$5.80 million-5.93
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.83-0.7%$434.41 million$335 million-0.96
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.01-0.9%$431.48 million$6.07 million-3.35News Coverage
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.6$8.61-1.7%$429.85 million$72.96 million-2.79Analyst Report
News Coverage
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.51-0.4%$429.41 millionN/A-3.47
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.15-0.0%$427.02 million$56.50 million0.00
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.07-0.4%$423.99 millionN/A0.00
BCEL
Atreca
1.7$11.41-0.4%$420.24 millionN/A-4.05
MedAvail logo
MDVL
MedAvail
1.9$12.89-4.1%$411.71 million$1.03 million-3.16
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.66-4.1%$411.29 million$6.68 million-4.41
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$33.01-3.1%$408.17 million$206.55 million-16.59
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.